CD274 and neoplasm: Three tumor-centric biomarkers; PD-L1 expression (≥ 1% or ≥ 50% of tumor cells), Microsatellite Instability (mutations in ≥30% of microsatellites/mismatch repair deficient), and Tumor Mutation Burden (TMB-H; ≥10 somatic mutations/Mb) are FDA-approved biomarkers for ICIs used to treat NSCLC (Figure 3B).